EPCAM and neoplasm: The multifunctional antibody catumaxomab binds both to the EpCAM tumor cell antigen and to CD3+ lymphocytes, enhancing antitumor activity by redirecting T-cells and Fcgamma receptor I/III-positive accessory cells to the tumor.